5-Amino-1MQ: the small molecule that inhibits NNMT
An inhibitor is a compound that slows an enzyme's activity. NNMT is an enzyme, a protein that speeds a chemical reaction inside cells.
ReadyPep Research Desk7 min read
5-Amino-1MQ is a small molecule studied for its ability to inhibit NNMT, an enzyme involved in cell chemistry. Cell and mouse studies can examine the compound, but they do not show what it does in people.
Key takeaways
- 5-Amino-1MQ is a quinolinium small molecule, not a peptide.
- NNMT adds a methyl group to nicotinamide and makes 1-MNA and SAH.
- Cell studies can test NNMT activity and lipid buildup in fat cells.
- Mouse studies do not establish effects in people.
- Cell and animal studies do not establish a safe human dose, route, or length of use.
- Research-use labeling does not make a compound an approved medicine.
What 5-Amino-1MQ is
5-Amino-1MQ, also called 5-amino-1-methylquinolinium, is a small molecule in the quinolinium family. Researchers have studied it as an inhibitor of nicotinamide N-methyltransferase, or NNMT.
An inhibitor is a compound that slows an enzyme's activity. NNMT is an enzyme, a protein that speeds a chemical reaction inside cells. It is not a cell-surface receptor, which is a protein at a cell's outer edge that receives signals.
5-Amino-1MQ is not a peptide. Peptides are short chains of amino acids, while this compound has a small-molecule chemical structure.
In lab tests, membrane-permeable means a compound can cross cell membranes in that test setup. This result does not show where the compound goes in a person or how the body handles it.
What NNMT does in cells
NNMT adds a methyl group to nicotinamide, a form of vitamin B3. A methyl group is a small chemical unit made from one carbon atom and three hydrogen atoms.
For this reaction, NNMT uses nicotinamide and S-adenosylmethionine (SAM), a cell molecule that supplies the methyl group. The reaction makes 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH), the product left after SAM gives up that group.
Nicotinamide can also enter the NAD+ salvage pathway, the set of steps cells use to remake NAD+, a helper molecule used in many cell reactions. Blocking NNMT may change how cells use nicotinamide, but it does not directly make NAD+.
SAM links the NNMT reaction to the methionine cycle, a set of cell steps that helps remake SAM after it donates a methyl group. A change in NNMT activity may affect this part of cell chemistry, but the size of that change depends on the cell system.
What cell studies have measured
Cell studies can measure NNMT activity and changes in fat cells.
Those results apply to the cells in the lab. A change in lipid buildup in fat cells does not prove a health benefit or the same change in a person.
Researchers also study other NNMT inhibitors and chemical relatives. A result from one of those compounds cannot be assigned to 5-Amino-1MQ unless that experiment tested 5-Amino-1MQ itself.
Selectivity tests compare a compound's effect on NNMT with its effects on other enzymes. Cell-permeability tests ask whether the compound enters cells under the test conditions. Neither test, by itself, shows how the compound acts throughout a person.
Lab studies can help show whether a compound affects a target enzyme and whether it enters certain cells. They cannot, on their own, establish a safe level, lasting effect, or useful outcome in people.
What animal research can tell us
Mouse studies can examine a compound in a whole living system.
The published preclinical report by Neelakantan and colleagues in Biochemical Pharmacology tested 5-Amino-1MQ in mice over a short treatment period. Compared with controls, treated mice showed lower body weight and fat mass, alongside lower circulating cholesterol. Food intake did not show a corresponding decrease, so the measured change was not simply explained by eating less; the experiment does not establish the mechanism.
The investigators reported no adverse effects during that experiment. This observation applies only to the short mouse protocol: it does not establish long-term safety, predict human effects, or show that the findings will carry over to people.
A result in mice does not establish the same response in people.
A mouse can show how a compound acts across a whole body, which a dish of cells cannot show. But mice and people can absorb, break down, and respond to compounds in different ways.
NNMT studies focus on cell chemistry and metabolism, the chemical steps cells use to make and use materials. That is not the same as testing a treatment designed to change eating signals.
What the evidence does not establish
Measures in cells or animals do not, by themselves, establish what a compound does in people.
A link between NNMT and a metabolic illness does not prove that blocking NNMT prevents or treats that illness. Showing a link and showing that a compound changes a health outcome are different steps.
Cell and mouse findings do not establish a safe or effective human dose, a suitable route, or how long an effect might last. They also do not establish how the compound is absorbed, broken down, or cleared in people.
People, mice, and lab-grown cells differ in many ways. A result in one model can guide later tests, but it cannot settle human response or safety.
Research status, safety, and product labeling
5-Amino-1MQ is a research compound; the FDA has not approved it as a medicine. A research-use label describes a lab context; it does not by itself establish approval as a medicine or safety for people.
Published human clinical-trial results for 5-Amino-1MQ are not available; the reported evidence remains preclinical. No published human results establish whether the mouse findings occur in people or establish safety in people.
Cell and mouse findings do not establish long-term safety in people. They also do not settle liver safety, interaction risks, or effects on particular organs.
Animal test amounts and lab protocols do not establish a human dose or route. Without suitable human evidence, they cannot be turned into a personal use plan.
When judging claims about this compound, keep the test model in view. A result from a cell experiment answers a different question from a mouse study, and neither answers how people will respond.
What should readers know about 5-Amino-1MQ?
How long does 5-Amino-1MQ take to work?
No human time to effect is established. The length of a cell experiment describes how long cells met the compound, not when a person would notice a change.
Is 5-Amino-1MQ harmful to the liver?
The available cell and mouse findings do not settle liver risk in people. Liver safety would need direct checks over time, such as blood tests and, where suitable, tissue review.
How long does 5-Amino-1MQ stay in the body?
No reliable human clearance time is established. Timed blood or tissue tests would be needed to track how levels rise and fall in the body.
Are there known drug or supplement interactions with 5-Amino-1MQ?
A human interaction profile has not been established. Tests would need to examine specific combinations, since findings for one medicine cannot predict every other medicine or supplement.
See also: Lab Testing, Certifications, How Readypep Works, Products, Research use only, Shipping, Why ReadyPep, Manufacturer-distributor split explained, Faq, Blog, Reading A Certificate Of Analysis, Cold Chain In Transit, Pre Filled Pens Versus Vials.
Conclusion
5-Amino-1MQ is a quinolinium small molecule studied for its effect on NNMT. Cell and mouse studies do not, by themselves, establish a safe or useful effect in people.